<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089294</url>
  </required_header>
  <id_info>
    <org_study_id>13771/2016</org_study_id>
    <nct_id>NCT03089294</nct_id>
  </id_info>
  <brief_title>Low Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: Standardisation of Treatment Protocol</brief_title>
  <official_title>Low Intensity Extracorporeal Shock Wave Treatment Patients With Vasculogenic Erectile Dysfunction: Standardisation of Treatment Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for the Study of Urological Diseases, Greece</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute for the Study of Urological Diseases, Greece</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to identify the efficacy saturation effect of low intensity&#xD;
      extracorporeal shockwave treatment (LI-ESWT) using Aries ED device in men with mild-moderate&#xD;
      and severe vasculogenic ED, who have previously responded to oral PDE5-Is. The efficacy and&#xD;
      safety of 4 different session frequency protocols will be compared.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, 4 parallel arms, clinical trial with an 18-month recruitment period.&#xD;
      All patients will be PDE5I users/responders. After 1 month wash-out period, ED patients will&#xD;
      be screened, in order to randomize 96 men with vasculogenic ED, an International Index of&#xD;
      Erectile Function ED (IIEF-ED) domain score between 6-25 and abnormal penile triplex-based&#xD;
      hemodynamic parameters (peak flow velocity &lt;35cm/sec) in the last 6 months. Additionally,&#xD;
      they will be asked to complete the SEP diaries. Patients will be randomized to receive&#xD;
      shockwave treatments (12 sessions for all subjects), either twice a week (total of 6 weeks)&#xD;
      or three times a week (total of 4 weeks) at energy level 4 or 7, without treatment interval.&#xD;
&#xD;
      Study visits and duration&#xD;
&#xD;
      Visit 1 (day 0): the basic work-up will take place, including medical and sexual history, as&#xD;
      well as necessary lab tests, if needed. One month wash-out period will follow. During this&#xD;
      period, all subjects will be asked to avoid any drug related to ED (PDE5i) and have at least&#xD;
      2-4 attempts for intercourse. Furthermore, patients will undergo triplex ultrasonography,&#xD;
      unless they have already done so in the last 6 months.Also penile dimensions in both flaccid&#xD;
      and erect state will be measured.&#xD;
&#xD;
      Visit 2 (day 28 + 3 days): all patients will complete the IIEF-ED domain and will be&#xD;
      randomized to one of the four parallel study groups, using an online program. Groups A and C&#xD;
      will receive treatment twice per week, at energy level 4 and 7 respectively. Groups B and D&#xD;
      will receive treatment three times per week, at energy level 4 and 7 respectively. PDE5i use&#xD;
      is prohibited throughout the study.&#xD;
&#xD;
      Treatment Visits: There will be 12 active treatment visits for all 4 Groups. Patients will&#xD;
      receive LI-ESWT, according to the study protocol. Interval between 2 treatments will be 3+1&#xD;
      days for Groups A and C (twice/week) whereas 1+1 day for Groups B and D (three times/week).&#xD;
      At visit 6 and 12 a penile ultrasonography will be conducted in order to check for potential&#xD;
      adverse events related to the treatment.&#xD;
&#xD;
      Follow-up visits 1 - 3 (4, 12 ,24 and 48 weeks post treatment): Patients will complete the&#xD;
      IIEF-ED questionnaire and return the completed SEP diaries for the last 4 weeks prior to&#xD;
      every visit. Visit data will also be recorded (protocol compliance, adverse events). At Week&#xD;
      12, triplex will be performed by the standard protocol. For Week 4 there is a + 3 days visit&#xD;
      window, whereas for weeks 12, 24 and 48 there is a + 2 weeks visit window.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 30, 2016</start_date>
  <completion_date type="Actual">December 10, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percent of subjects who achieve clinically important difference (MCID) in the EF domain score of the IIEF</measure>
    <time_frame>baseline and 6 month follow up visit</time_frame>
    <description>MCID is defined according to baseline ED severity as:&#xD;
Improvement by 2 or more in the EF domain score of the IIEF for patients with mild ED ( EF scores 17-25) at baseline.&#xD;
Improvement by 5 or more in the EF domain score of the IIEF for patients with moderate ED(EF scores 11-16) at baseline&#xD;
Improvement by 7 or more in the EF domain score of the IIEF for patients with severe ED (EF scores 0-10) at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the EF domain score of the IIEF</measure>
    <time_frame>baseline, 6 month follow up visit and 12 month follow up visit</time_frame>
    <description>EF domain of the IIEF questionnaire will be completed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sexual Encounter Profile Question 3 (SEP3) score</measure>
    <time_frame>baseline, 6 month follow up visit and 12 month follow up visit</time_frame>
    <description>The percent of subjects who answer ''YES'' in question 3 of SEP questionnaire will be reported</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean peak systolic velocity (PSV)</measure>
    <time_frame>baseline and 3 month follow up visit</time_frame>
    <description>Mean peak systolic velocity will be measured by penile triplex ultrasonography by the same investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment related adverse events</measure>
    <time_frame>54 weeks (Group A and Group C), 52 weeks (Group B and Group D)</time_frame>
    <description>Potential treatment related adverse events after the first LI-ESWT session and during the 12 month follow up period will be reported</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 4 (12 sessions totally)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 4 (12 sessions totally)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 2 sessions of LI-ESWT per week for a 6 week period with energy level 7 (12 sessions totally)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 3 sessions of LI-ESWT per week for a 4 week period with energy level 7 (12 sessions totally)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aries ED device</intervention_name>
    <description>The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Consent to participate&#xD;
&#xD;
          2. Age &gt;18&#xD;
&#xD;
          3. Presence of vasculogenic erectile dysfunction for at least 6 months&#xD;
&#xD;
          4. Positive response to PDE5i&#xD;
&#xD;
          5. IIEF-ED score &gt; 6 and IIEF score &lt; 26 after wash out of PDE5i&#xD;
&#xD;
          6. Abnormal penile triplex-based hemodynamic parameters (peak flow velocity &lt;35cm/sec)&#xD;
&#xD;
          7. Stable heterosexual relationship for more than 3 months&#xD;
&#xD;
          8. Sexually active and agree to suspend all ED therapy for the duration of study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any cause of ED other than vascular related&#xD;
&#xD;
          2. Previous radiation therapy to pelvis&#xD;
&#xD;
          3. History of radical prostatectomy&#xD;
&#xD;
          4. Clinically significant chronic haematological disease&#xD;
&#xD;
          5. Cardiovascular conditions that prevent sexual activity&#xD;
&#xD;
          6. Peyronie's Disease or penile curvature&#xD;
&#xD;
          7. History of heart attack, stroke or any life- threatening arrhythmia within the prior 6&#xD;
             month&#xD;
&#xD;
          8. Anti-androgens oral or injectables androgens&#xD;
&#xD;
          9. Untreated Hypogonadism as demonstrated by abnormal testosterone levels&#xD;
&#xD;
         10. Malignancy within the past 5 years&#xD;
&#xD;
         11. Any unstable medical, psychiatric condition or spinal cord injury&#xD;
&#xD;
         12. Anatomical or neurological abnormalities in the treatment area&#xD;
&#xD;
         13. Use of any treatment for ED within 7 days of screening ( oral medications, vacuum&#xD;
             devices, constrictive devices, injections or urethral suppositories)&#xD;
&#xD;
         14. Known allergy to ultrasound gel&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dimitrios Hatzichristou, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for the Study of Urological Diseases (ISUD)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>G.Gennimatas Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Clavijo RI, Kohn TP, Kohn JR, Ramasamy R. Effects of Low-Intensity Extracorporeal Shockwave Therapy on Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2017 Jan;14(1):27-35. doi: 10.1016/j.jsxm.2016.11.001. Epub 2016 Dec 13. Review.</citation>
    <PMID>27986492</PMID>
  </reference>
  <reference>
    <citation>Lu Z, Lin G, Reed-Maldonado A, Wang C, Lee YC, Lue TF. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol. 2017 Feb;71(2):223-233. doi: 10.1016/j.eururo.2016.05.050. Epub 2016 Jun 16. Review.</citation>
    <PMID>27321373</PMID>
  </reference>
  <reference>
    <citation>Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011 Nov;60(5):1010-6. doi: 10.1016/j.eururo.2011.07.053. Epub 2011 Jul 30.</citation>
    <PMID>21855209</PMID>
  </reference>
  <reference>
    <citation>Gruenwald I, Kitrey ND, Appel B, Vardi Y. Low-Intensity Extracorporeal Shock Wave Therapy in Vascular Disease and Erectile Dysfunction: Theory and Outcomes. Sex Med Rev. 2013 Jul;1(2):83-90. doi: 10.1002/smrj.9. Epub 2015 Oct 18. Review.</citation>
    <PMID>27784587</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 24, 2019</last_update_submitted>
  <last_update_submitted_qc>March 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for the Study of Urological Diseases, Greece</investigator_affiliation>
    <investigator_full_name>Dimitrios Hatzichristou</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>Erectile Dysfunction</keyword>
  <keyword>Low intensity extracorporeal shock wave treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

